跳至主要内容
临床试验/ACTRN12613000419763
ACTRN12613000419763尚未招募未知

An open-label, prospective pilot study evaluating the effect of adalimumab on endothelial function and on cardiovascular biomarkers in severe chronic plaque psoriasis patients eligible for biologic treatment in Australia

Dr Anna Braue0 个研究点目标入组 15 人开始时间: 2013年4月15日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Patient who has had severe chronic plaque psoriasis for at least 6 months with no previous exposure to biologics, and is eligible for biologics as per Australian PBS requirements and has been selected to start adalimumab by a dermatologist

排除标准

  • Patients not starting on adalimumab as their first biological agent or has had prior biologic treatment

研究者

发起方
Dr Anna Braue

相似试验

A prospective study to assess the effect of... | 临床试验